Sanofi

News

Galderma's chief executive Flemming Ørnskov

Galderma gets FDA nod for prurigo nodularis therapy

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales.

News

NICE updates on controversial multiple myeloma decisions

NICE has defended a trio of decisions on new therapies for multiple myeloma, which saw two drugs approved for restricted use in England and Wales and a third turned down altogether.

News

European big pharmas raise guidance on stronger sales

AstraZeneca, Roche, and Sanofi released their second-quarter results today, with a common theme – strong sales growth that caused them to raise their financial guidance for the year.

News

MSD stakes claim to RSV prevention market for infants

MSD has reported phase 2b/3 data with its clesrovimab antibody for respiratory syncytial virus (RSV) preventions in infants, which could be a challenger to Sanofi and AstraZeneca's fast-gro

News

Private equity firms ‘eyeing $20bn for Sanofi consumer unit’

Private equity firms Bain Capital and Cinven are reported to be considering a bid for Sanofi’s consumer health business, according to Bloomberg.

News

EU first to approve Dupixent for COPD

Chronic obstructive pulmonary disease (COPD) has seen no new therapies brought to market for around 10 years – and now there have been two in the space of a couple of weeks.

Galderma gets FDA nod for prurigo nodularis therapy

NICE updates on controversial multiple myeloma decisions

European big pharmas raise guidance on stronger sales

MSD stakes claim to RSV prevention market for infants

Private equity firms ‘eyeing $20bn for Sanofi consumer unit’

EU first to approve Dupixent for COPD

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Sanofi

Editor's Picks